二苯亚甲基甘氨酸甲酯 | 81167-39-7

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 甘氨酸类衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 二苯亚甲基甘氨酸甲酯
• 中文别名: N-(二苯基亚甲基)甘氨酸甲酯
• 英文名称: ethyl N-benzhydrylideneglycinate
• 英文别名: methyl N-(diphenylmethylene)glycinate；methyl 2-[(diphenylmethylidene)amino]acetate；methyl 2-((diphenylmethylene)amino)acetate；methyl 2-(benzhydrylideneamino)acetate；N-(Diphenylmethylene)glycine methyl ester
• CAS: 81167-39-7
• 化学式: C₁₆H₁₅NO₂
• 分子量: 253.301
• InChiKey: PQTOLHHWLUCKSB-UHFFFAOYSA-N

物化性质

• 熔点：
  42-44?C
• 沸点：
  342.8±34.0 °C(Predicted)
• 密度：
  1.05±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  38.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2925290090
• 危险性防范说明：
  P261,P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H332,H335
• 储存条件：
  在惰性气氛下存储的冰箱

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: N-(Diphenylmethylene)glycine methyl ester
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: N-(Diphenylmethylene)glycine methyl ester
CAS number: 81167-39-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C16H15NO2
Molecular weight: 253.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

2-((二苯亚甲基)氨基)乙酸甲酯是甘氨酸（HY-Y0966）的衍生物。

反应信息

• 作为反应物：
  描述：

  二苯亚甲基甘氨酸甲酯 在 palladium on activated charcoal N,N-二甲基丙烯基脲 、 正丁基锂 、 三正丁基氢锡 、 二异丙胺 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 4.5h， 生成 4-戊烯酸,2-[(二苯亚甲基)氨基]-,甲基酯
  参考文献：
  名称：

  炔丙基甘氨酸衍生物的氢化锡安

  摘要：

  研究了由多种过渡金属配合物引起的（R，S）-2-（N-二苯基亚甲基）氨基戊4-羟甲基的氢化锡氢化反应。所得的异构体α-氨基酸衍生物在侧链上具有三丁基乙烯基锡烷，并通过色谱法分离。试图针对该反应筛选总共24个不同条件，以试图将炔丙基的区域选择性加氢氢化三丁基锡在所有情况下均形成区域异构混合物，并且对于某些催化剂而言，还原为烯丙基甘氨酸衍生物也很重要。

  DOI：

  10.1016/s0022-328x(96)06752-6
• 作为产物：
  描述：

  二苯甲酮亚胺 、 溴乙酸甲酯 在 N,N-二异丙基乙胺 作用下， 以 乙腈 为溶剂， 反应 12.0h， 以70%的产率得到二苯亚甲基甘氨酸甲酯
  参考文献：
  名称：

  [EN] NOVEL SELECTIVE KAPPA OPIOID RECEPTOR ANTAGONISTS AND METHODS RELATED THERETO FOR TREATMENT OF ADDICTION AND NEUROPATHIC PAIN
  [FR] NOUVEAUX ANTAGONISTES SÉLECTIFS DU RÉCEPTEUR OPIOÏDE KAPPA ET PROCÉDÉS S'Y RAPPORTANT POUR LE TRAITEMENT DE LA DÉPENDANCE ET DE LA DOULEUR NEUROPATHIQUE

  摘要：

  揭示了一种治疗方法和组合物，能够对抗某些疾病，如成瘾、酒精依赖、阿片类药物滥用治疗、神经系统疾病、神经病性疼痛以及其组合。这些化合物通过作为kappa (K) 阿片受体的选择性拮抗剂来发挥作用，当存在时，会导致疾病的抑制，相较于已知治疗方法，提供了更高的效果。揭示的化合物还表现出高效穿越血脑屏障的能力。揭示的化合物在纳摩尔范围内显示出有效性。

  公开号：

  WO2020092996A1
• 作为试剂：
  描述：

  N-[苄氧羰基]谷氨酸 5-叔丁酯 在 氢气 、 二苯亚甲基甘氨酸甲酯 、 三乙胺 、 氯甲酸异丁酯 作用下， 以 2-甲基四氢呋喃 为溶剂， 反应 3.17h， 生成 tert-butyl 4,5-diamino-5-oxopentanoate
  参考文献：
  名称：

  [EN] PROCESSES FOR PREPARATION OF (S)-TERT-BUTYL 4,5-DIAMINO-5-OXOPENTANOATE
  [FR] PROCÉDÉS DE PRÉPARATION DE (S)-TERT-BUTYL 4,5-DIAMINO-5-OXOPENTANOATE

  摘要：

  提供了制备(S)-叔丁基4,5-二氨基-5-氧代戊酸酯，或其盐、溶剂结晶体、水合物、对映体、对映体混合物或同位素类似物的方法。还提供了从这些过程中获得的各种中间体和产物的固体形式。

  公开号：

  WO2019040109A1

文献信息

• HEPATITIS C VIRUS INHIBITORS AND USES THEREOF IN PREPARATION OF DRUGS
  申请人：CHANGZHOU YINSHENG PHARMACEUTICAL CO., LTD.

  公开号：US20170253614A1

  公开（公告）日：2017-09-07

  A series of hepatitis C virus (HCV) inhibitors and compositions and applications thereof in the preparation of drugs for treating chronic HCV infection. Especially, a series of compounds that are used as NS5A inhibitors, and compositions and uses thereof in the preparations of drugs.

  一系列丙型肝炎病毒（HCV）抑制剂及其组合物，以及在制备用于治疗慢性HCV感染的药物时的应用。特别是一系列用作NS5A抑制剂的化合物，以及在药物制剂中的组合物和用途。
• Oxygen Alkylation of Schiff Base Derivatives of Amino Acids
  作者：Martin J. O'Donnell、Gwendolyn K. Cook、David B. Rusterholz

  DOI：10.1055/s-1991-26625

  日期：——

  Higher imine esters 1a-h and 7a-b of amino acids and dipeptides are prepared in 68-91% yield by saponification of the benzophenone Schiff base methyl esters 3a-d and 6 using phase-transfer techniques followed by O-alkylation with an alkyl halide. The procedure occurs with retention of configuration at the α-carbon except with phenylglycine derivatives.

  氨基酸和二肽的高亚胺酯1a-h和7a-b通过皂化苯甲酮席夫碱甲酯3a-d和6，采用相转移技术，随后与烷基卤进行O-烷基化，产率在68-91%之间。该过程在α-碳上保留构型，除了苯基甘氨酸衍生物外。
• Metal complexes of biologically important ligands, XCVII. Synthesis and characterisation of cyclometallated compounds of Schiff bases from α-amino acid esters with manganese (I) and rhenium (I) carbonyls
  作者：Andreas Böhm、Karlheinz Sünkel、Kurt Polborn、Wolfgang Beck

  DOI：10.1016/s0022-328x(97)00579-2

  日期：1998.2

  N-Diphenylmethylen Schiff bases from α-amino acid esters react with MnMe(CO)5 and ReMe(CO)5 in refluxing octane to give the orthometallated complexes (CO)4M[C6H4(C6H5)CNCHR1CO2R2}-C,N] (MMn, Re). Reactions of the orthometallated rhenium complexes with HBF4 afford ionic N,O-chelate complexes under cleavage of the Re–C bond. The structures of the valine derivatives of the orthomanganated and -rhenated

  ñ从-Diphenylmethylen Schiff碱α -氨基酸的酯与MnMe（CO）反应5和雷默（CO）5在回流辛烷，得到orthometallated络合物（CO）4 M [C 6 H ^ 4（C 6 H ^ 5）C NCHR 1 CO 2 - [R 2 } -C，N]（MMn中，Re）。在Re-C键断裂的情况下，原金属化的–配合物与HBF 4的反应生成离子型N，O-螯合物。通过X-射线衍射测定正锰和正hen的配合物的缬氨酸衍生物的结构。
• [EN] COMPOUNDS FOR INHIBITION OF ALPHA 4 BETA 7 INTEGRIN<br/>[FR] COMPOSÉS POUR L'INHIBITION DE L'INTÉGRINE ALPHA 4 BÊTA 7
  申请人：GILEAD SCIENCES INC

  公开号：WO2020092383A1

  公开（公告）日：2020-05-07

  The present disclosure provides a compound of Formula (I): or a pharmaceutically acceptable salt thereof as described herein. The present disclosure also provides pharmaceutical compositions comprising a compound of Formula (I), processes for preparing compounds of Formula (I), and therapeutic methods for treating inflammatory disease.

  本公开提供一种如下式（I）的化合物或其药用可接受的盐。本公开还提供包括如下式（I）化合物的药物组合物，制备如下式（I）化合物的方法，以及治疗炎症性疾病的治疗方法。
• [EN] NOVEL DUAL MODE OF ACTION SOLUBLE GUANYLATE CYCLASE ACTIVATORS AND PHOSPHODIESTERASE INHIBITORS AND USES THEREOF<br/>[FR] NOUVEAUX ACTIVATEURS DE LA GUANYLATE CYCLASE SOLUBLE À DOUBLE MODE D'ACTION ET INHIBITEURS DE PHOSPHODIESTÉRASE ET LEURS UTILISATIONS
  申请人：TOPADUR PHARMA AG

  公开号：WO2021245192A1

  公开（公告）日：2021-12-09

  The present invention relates to compounds of formula (I), or pharmaceutically acceptable salt, solvate or hydrate thereof, wherein said compound of formula (I) comprises at least one covalently bound -ONO2 or -ONO moiety and at most four covalently bound -ONO2 or -ONO moieties, and wherein AR, R1, X, R3 and R4 are as defined in claim 1; and pharmaceutical compositions thereof, and their use in methods of treating or preventing a disease alleviated by inhibition of PDE5 in a human or in a non-human mammal.

  本发明涉及式(I)的化合物，或其药学上可接受的盐、溶剂或水合物，其中所述式(I)的化合物至少包括一个共价结合的-ONO2或-ONO基团，最多包括四个共价结合的-ONO2或-ONO基团，其中AR、R1、X、R3和R4如权利要求1所定义；以及其药物组合物，以及它们在治疗或预防通过抑制人类或非人类哺乳动物中的PDE5而缓解的疾病的方法中的使用。